• Country
    Clear
  • Thematic
    Clear
  • Type
  • Compatibility Level
  • Jurisdiction
3,394 Data sources

  • NL
  • DE
  • FR
  • SG
  • Thematic: No

  • more_vert
  • more_vert
  • MADIS is the open access institutional repository of Ifsttar laboratories and jointly Managed Research Units (UMRs) productions. It is managed by the Library staff of Ifsttar. The interface is in French.

    more_vert
  • more_vert
  • more_vert
  • The repository is used for the publication, the proof and the long-term archiving of electronic documents. The interface is available in German and English.

    more_vert
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • more_vert
  • more_vert
  • more_vert
  • chevron_left
  • 5
  • 6
  • 7
  • 8
  • 9
  • chevron_right
3,394 Data sources
  • more_vert
  • more_vert
  • MADIS is the open access institutional repository of Ifsttar laboratories and jointly Managed Research Units (UMRs) productions. It is managed by the Library staff of Ifsttar. The interface is in French.

    more_vert
  • more_vert
  • more_vert
  • The repository is used for the publication, the proof and the long-term archiving of electronic documents. The interface is available in German and English.

    more_vert
  • Nearly 60% of patients undergoing cancer treatment are estimated to have had at least one potential drug-drug interaction; for patients receiving oral anticancer therapy, up to 50% have been reported to experience a potential drug-drug interaction, with 16% experiencing a major event. Drug-drug interactions are therefore a significant issue for cancer patients and the health care professionals who treat them. Combining the internationally recognised drug-drug interactions expertise of the University of Liverpool (UK) with the clinical pharmacology in oncology and haemotology expertise of Radboud University, Nijmegen (the Netherlands), this site was established in 2017 in response to the need for improved management of DDIs with anti-cancer agents.

    more_vert
  • more_vert
  • more_vert
  • more_vert
  • chevron_left
  • 5
  • 6
  • 7
  • 8
  • 9
  • chevron_right